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A Randomized Controlled Trial of a
Paclitaxel-Eluting Stent Versus a Similar
Bare-Metal Stent in Saphenous Vein Graft Lesions
The SOS (Stenting Of Saphenous Vein Grafts) Trial
Emmanouil S. Brilakis, MD, PHD,*† Christopher Lichtenwalter, MD,*† James A. de Lemos, MD,*†
Michele Roesle, RN,* Owen Obel, MD,*† Donald Haagen, RCIS,* Bilal Saeed, MD,‡
Chiranjeevi Gadiparthi, MD,*† Joseph K. Bissett, MD,§ Rajesh Sachdeva, MD,§
Vassilios V. Voudris, MD, PHD, Panagiotis Karyofillis, MD, Biswajit Kar, MD,¶
James Rossen, MD,# Panayotis Fasseas, MD,** Peter Berger, MD,†† Subhash Banerjee, MD*†
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Objectives The aim of this study was to compare the frequency of angiographic restenosis and clinical events between a
paclitaxel-eluting stent (PES) and a similar bare-metal stent (BMS) in saphenous vein graft (SVG) lesions.
Background There are conflicting and mostly retrospective data on outcomes after drug-eluting stent implantation in SVGs.
Methods Patients requiring SVG lesion stenting were randomized to BMS or PES. The primary study end point was binary
in-segment restenosis at 12-month follow-up quantitative coronary angiography. Secondary end points included
death, myocardial infarction, ischemia-driven target vessel and lesion revascularization, and target vessel failure.
Results Eighty patients with 112 lesions in 88 SVGs were randomized to a BMS (39 patients, 43 grafts, 55 lesions) or
PES (41 patients, 45 grafts, 57 lesions). Binary angiographic restenosis occurred in 51% of the BMS-treated le-
sions versus 9% of the PES-treated lesions (relative risk: 0.18; 95% confidence interval [CI]: 0.07 to 0.48, p 
0.0001). During a median follow-up of 1.5 years the PES patients had less target lesion revascularization (28%
vs. 5%, hazard ratio: 0.38; 95% CI: 0.15 to 0.74, p  0.003) and target vessel failure (46% vs. 22%, hazard ratio:
0.65; 95% CI: 0.42 to 0.96, p  0.03), a trend toward less target vessel revascularization (31% vs. 15%, hazard
ratio: 0.66; 95% CI: 0.39 to 1.05, p  0.08) and myocardial infarction (31% vs. 15%, hazard ratio: 0.67; 95% CI:
0.40 to 1.08, p  0.10), and similar mortality (5% vs. 12%, hazard ratio: 1.56; 95% CI: 0.72 to 4.11, p  0.27).
Conclusions In SVG lesions, PES are associated with lower rates of angiographic restenosis and target vessel failure than
BMS. (The SOS [Stenting Of Saphenous Vein Grafts] Randomized-Controlled Trial; NCT00247208) (J Am Coll
Cardiol 2009;53:919–28) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.11.029i
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The SOS Trial March 17, 2009:919–28during follow-up (2,3). No pro-
spective trial has specifically exam-
ined the outcomes after paclitaxel-
eluting stent (PES) implantation
in SVGs.
We performed the multi-
center, randomized SOS (Stent-
ing Of Saphenous Vein Grafts)
trial to compare the angiographic
and clinical outcomes after im-
plantation of a PES versus BMS
in SVG lesions.
Methods
Study design. The SOS trial
(NCT00247208) is a randomized,
controlled, multicenter, prospec-
tive trial designed to test the
hypothesis that implantation of
a polymer-based PES (Taxus,
Boston Scientific, Natick, Mas-
sachusetts) in SVG lesions is as-
sociated with a reduced 12-month
binary angiographic restenosis rate
compared with a BMS with simi-
lar design (Express2, Boston Sci-
entific). The trial was single-
linded: patients and outcome assessors were blinded, but the
nterventional cardiologists and physicians treating the patients
ere not.
See page 929
The study was performed at 5 clinical sites: Dallas
eterans Affairs Medical Center, Dallas, Texas (which also
erved as the coordinating center); Little Rock Veterans
ffairs Medical Center, Little Rock, Arkansas; Michael E.
eBakey Veterans Affairs Medical Center, Houston, Texas;
owa Veterans Affairs Medical Center, Iowa City, Iowa; and
nassis Cardiac Surgery Center, Athens, Greece. The study
as approved by the institutional review board of each
articipating institution.
atients. The inclusion criteria for the study were: 1) age
18 years; 2) 1 or more 50% to 99% de novo or restenotic
esions in an SVG that were between 2.5 and 4.0 mm in
iameter; 3) need for percutaneous coronary intervention
PCI) in the opinion of the attending cardiologist; and 4)
illingness to return for repeat graft angiography at 12
onths and be contacted after 1, 6, 12, and 24 months for
linical follow-up.
Exclusion criteria were: 1) prior brachytherapy in the
arget vessel; 2) left ventricular ejection fraction 25%; 3)
emorrhagic diatheses; 4) contraindications or allergy to
spirin, thienopyridines, paclitaxel, or stainless steel; 5)
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
CI  confidence interval
CK-MB  creatine kinase-
myocardial band
DES  drug-eluting stent(s)
EPD  embolic protection
device
MI  myocardial infarction
MLD  minimal lumen
diameter
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
SVG  saphenous vein
graft
TLR  target lesion
revascularization
TVR  target vessel
revascularizationistory of anaphylaxis to iodinated contrast medium; 6) use wf paclitaxel within 12 months before study entry or current
se of colchicine; 7) serum creatinine level 2.0 mg/dl; 8)
eukocyte count 3,500/mm3; 9) platelet count 100,000/
m3; 10) recent positive pregnancy test, breast-feeding, or
ossibility of a future pregnancy; and 11) coexisting condi-
ions limiting life expectancy to 24 months or that could
ffect a patient’s compliance with the protocol.
andomization. After eligible patients provided written
nformed consent, they were randomized in a 1:1 ratio to
reatment with either PES or BMS. Randomization was
one with sealed, opaque, sequentially numbered envelopes.
he allocation schedule was based on computer-generated
andom numbers and stratified according to study center,
ith block sizes of 4 to 8, which varied randomly.
tudy treatment. Before stenting, all patients received oral
spirin (325 mg daily) and oral clopidogrel (a loading dose
f 300 to 600 mg) as soon as possible but within 24 h of the
rocedure. Patients receiving daily clopidogrel for 72 h
efore stenting were not required to receive a clopidogrel
oading dose.
Anticoagulation during PCI was achieved with heparin
r bivalirudin at the operator’s discretion. If heparin was
sed, additional intravenous heparin boluses were adminis-
ered for a target activated clotting time (measured by the
emochron device) of 250 s. Heparin and bivalirudin
ere discontinued immediately after the procedure. The use
f intravenous glycoprotein IIb/IIIa inhibitors was left to
he discretion of the operator.
Balloon dilation before stent placement was not required.
ne or more stents of the assigned type were used to treat
he target lesion and edge dissections of types B through E
r for otherwise suboptimal results. The use of embolic
rotection devices (EPDs) and intravascular ultrasound
ere strongly encouraged. It was recommended that cardiac
iomarkers be measured before the intervention and 8 h and
6 to 24 h after the procedure.
Aspirin was administered indefinitely after stenting. Clo-
idogrel was initially recommended for 6 months after PES
lacement and for at least 1 month after BMS placement.
ince December 2006, a minimum of 1 year of clopidogrel
as recommended after PES placement.
linical and angiographic follow-up. Patients were asked
o return for repeat coronary angiography 12 months after
nrollment and contacted by phone at 1, 6, 12, and 24
onths after enrollment to assess whether any cardiovascu-
ar events had occurred. Hospital records and coronary
ngiograms were obtained to determine whether any clinical
r angiographic end points had occurred.
uantitative coronary angiography. Quantitative angio-
raphic analyses were performed blinded to the patient’s
dentity, type of stent used, outcome, and film sequence.
he stents used in the study are angiographically indistin-
uishable. Matched projections of coronary angiograms
btained at baseline, on completion of the stenting proce-
ure, and at follow-up coronary angiography at 12 months
ere analyzed with the CAAS automated edge detection
s
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March 17, 2009:919–28 The SOS Trialystem version 5.4. (Pie Medical Imaging, Maastricht, the
etherlands). The projection that best showed the stenosis
n its tightest view was selected. The intraobserver and
nterobserver correlation coefficients of the quantitative
oronary angiography measurements ranged from 0.90 to
.97 and 0.92 to 0.99, respectively.
The minimal lumen diameter (MLD) and nearest normal
eference diameter were measured in millimeters by using
he catheter as a scaling factor. Percent stenosis was calcu-
ated as 100  [1  (MLD/reference vessel diameter)].
cute gain was defined as the difference between the
aseline MLD and the in-stent MLD after stent implan-
ation. Late luminal loss was defined as the difference
etween the MLD at the end of the stenting procedure and
t follow-up angiography. Quantitative angiographic mea-
urements of the target lesion were obtained in the “in-
tent” zone (including only the stent segment) and “in-
egment” zone (the stented segment and the 5-mm
roximal and distal to the stent).
For every study SVG, a degeneration score was calculated
ccording to Coolong et al. (4), as an ordinal metric of the
xtent of lumen irregularities and ectasia (20% of the
eference normal segment) within the SVG, as follows:
25% of the total SVG length (SVG degeneration score:
), 26% to 50% (SVG degeneration score: 1), 51% to 75%
SVG degeneration score: 2), or 75% (SVG degeneration
core: 3).
nd points. The primary end point of the study was binary
ngiographic restenosis/lesion, defined as a stenosis of
Figure 1 Flowchart of the Patients Enrolled in the SOS (Stentin
BMS  bare-metal stent(s); CABG  coronary artery bypass grafting; FU  follow-u50% of the MLD in the target SVG segment at 12-month angiographic follow-up. Comparison of angiographic reste-
osis was also performed for each saphenous vein graft and
atient. If multiple lesions were treated in the same graft of
he same patient, angiographic restenosis was considered to
ave occurred if any lesion developed in-segment restenosis.
Secondary end points included procedural success, death,
yocardial infarction (MI), ischemia-driven target lesion
evascularization (TLR) and target vessel revascularization
TVR), target vessel failure, overall major adverse cardiac
vents, cerebrovascular events, stent thrombosis, and intra-
tent intimal hyperplasia accumulation at follow-up, as
easured by intravascular ultrasound (the intravascular
ltrasonography data have not yet been analyzed and are not
ncluded in this report).
Procedural success was defined as the achievement of
esidual in-stent stenosis of 30%, associated with Throm-
olysis In Myocardial Infarction (TIMI) flow grade 3 (or at
east similar flow to the baseline flow if the baseline flow was
IMI flow grade 1 or 2), in the absence of a dissection
orse than D1, as assessed according to the National Heart,
ung, and Blood Institute classification, without the occur-
ence of death, MI, or repeat TLR during the index hospital
tay (5). Post-PCI acute MI was defined as a post-
rocedural rise in creatine kinase-myocardial band (CK-
B) (measured after 8 h and 16 to 24 h from PCI) 3
imes the upper limit of normal.
All deaths were considered to be cardiac unless an
nequivocal noncardiac cause could be established. Myocar-
ial infarction during follow-up was defined as typical rise
Saphenous Vein Grafts) Trial
 paclitaxel-eluting stent(s).g Of
p; PESnd fall of troponin or CK-MB above the upper limit of
922 Brilakis et al. JACC Vol. 53, No. 11, 2009
The SOS Trial March 17, 2009:919–28Baseline Characteristics of the Study Population
Table 1 Baseline Characteristics of the Study Population
BMS
(Patients  39, Grafts  43,
Lesions  55, Stents  62)
PES
(Patients  41, Grafts  45,
Lesions  57, Stents  62) p Value
Age (yrs)* 67 9 66 9 0.71
Men 39 (100%) 41 (100%) 1.0
Inpatient 27 (69%) 30 (73%) 0.70
Ethnicity 0.19
White 35 (90%) 40 (98%)
Black 1 (3%) 1 (2%)
Hispanic 3 (7%) 0 (0%)
Years since coronary artery bypass surgery* 12 6 11 6 0.84
Indication for PCI 0.53
Stable angina 13 (33%) 12 (29%)
Unstable angina 14 (36%) 16 (39%)
Non–ST-segment elevation acute MI 8 (21%) 10 (24%)
Other 4 (10%) 3 (7%)
Hypertension 37 (95%) 38 (93%) 0.69
Hyperlipidemia 37 (95%) 40 (98%) 0.53
Diabetes mellitus 17 (44%) 18 (44%) 0.98
Current smoking 9 (23%) 12 (29%) 0.53
Prior MI 23 (59%) 23 (56%) 0.79
Body mass index (kg/m2)* 28.9 3.9 29.9 4.6 0.32
Ejection fraction, n/total (%) 0.53
50% 22/36 (61%) 20/39 (51%)
40–49% 9/36 (25%) 11/39 (28%)
30–39% 4/36 (11%) 4/39 (10%)
30% 0/36 (0%) 4/39 (10%)
Number of SVGs treated/patient* 1.15 0.37 1.12 0.33 0.68
1 33 (85%) 36 (88%) 0.68
2 6 (15%) 5 (12%)
Number of lesions treated/patient* 1.41 0.64 1.39 0.70 0.89
1 26 (67%) 29 (71%) 0.71
2 10 (26%) 9 (22%)
3 3 (8%) 2 (5%)
4 0 1 (2%)
Number of stents/patient* 1.56 0.72 1.54 0.84 0.56
1 22 (56%) 27 (66%) 0.41
2 12 (31%) 7 (17%)
3 5 (13%) 6 (15%)
4 0 1 (2%)
Lesion location 0.80
Aortic anastomosis 15 (27%) 15 (26%)
Proximal third 11 (20%) 16 (28%)
Mid third 18 (33%) 17 (30%)
Distal third 7 (13%) 5 (9%)
Coronary anastomosis 4 (7%) 4 (7%)
Restenotic lesions 7 (7%) 9 (16%) 0.16
Recipient vessel for each study graft
LAD/diagonal 13 (30%) 12 (27%) 0.37
Circumflex/OM 13 (30%) 20 (44%)
RCA/PDA 17 (40%) 13 (29%)
Number of lesions treated in each study SVG* 1.28 0.50 1.27 0.50 0.91
1 32 (74%) 34 (76%) 0.99
2 10 (23%) 10 (22%)
3 1 (2%) 1 (2%)
Continued on next page
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March 17, 2009:919–28 The SOS Trialormal, with either ischemic symptoms or electrocardio-
raphic changes indicative of ischemia (ST-segment eleva-
ion or depression or development of pathologic Q waves)
6). Ischemia-driven TVR and TLR were defined as repeat
CI or coronary artery bypass grafting performed because of
estenosis of the target vessel or lesion, respectively, in
ssociation with angina or objective evidence of myocardial
schemia.
Target vessel failure was defined as the composite end
oint of cardiac death, MI, and TVR. A composite end
Continued
Table 1 Continued
(Patients
Lesions 
Number of stents in each study SVG* 1
1
2
3
Percent SVG degeneration*
SVG degeneration score
0
1
2
3
Number of stents/lesion* 1
1
2
Pre-stenting TIMI flow grade
1
2
3
Post-stenting TIMI flow grade
2
3
Embolic protection device use
Pre-dilation
Post-dilation
Total stent length/patient (mm)*
Range
Total stent length/lesion (mm)*
Range
Maximum balloon diameter (mm)* 3
Maximum inflation pressure (atm)* 1
Stent length (mm)*
Stent diameter (mm)* 3
Contrast use (ml)* 2
Fluoroscopy time (min)*
Medications at the time of PCI
Anticoagulation†
Unfractionated heparin
Bivalirudin
Glycoprotein IIb/IIIa inhibitor
Post-PCI MI 2
Bare-metal stent (BMS) patients: n  39; 43 grafts, 55 lesions, 62 ste
stents. Values are n (%) unless otherwise indicated. *Mean SD. †One
received both heparin and bivalirudin.
LAD  left anterior descending artery; MI  myocardial infarction;
posterior descending artery; RCA  right coronary artery; SVG  saphoint of cardiac death, MI attributed to the target vessel, and TLR was also evaluated (device-oriented composite
nd point, as suggested by Cutlip et al. [7]). If an adverse
vent could not unequivocally be attributed to a nontarget
essel, the event was considered to represent target vessel
ailure. We also assessed the incidence of major adverse
ardiac events defined as the composite of any death, any
I, or any coronary revascularization (similar to the
atient-oriented composite end point suggested by Cut-
ip et al. [7]).
In the original protocol, stent thrombosis was defined as
S
Grafts  43,
tents  62)
PES
(Patients  41, Grafts  45,
Lesions  57, Stents  62) p Value
0.63 1.40 0.65 0.55
5%) 31 (69%) 0.81
8%) 10 (22%)
%) 4 (9%)
19 33 20 0.38
7%) 22 (49%) 0.52
7%) 15 (33%)
3%) 6 (13%)
%) 2 (4%)
0.34 1.09 0.29 0.50
7%) 52 (91%) 0.50
3%) 5 (9%)
0.17
%) 3 (5%)
0%) 4 (7%)
8%) 50 (88%)
0.16
%) 1 (2%)
3%) 56 (98%)
6%) 29 (51%) 0.56
9%) 19 (33%) 0.63
4%) 9 (16%) 0.30
16 28 17 0.74
8 8–84
9 20 10 0.75
0 8–56
0.48 3.30 0.52 0.40
2.5 16.6 3.1 0.37
6 18 6 0.90
0.42 3.14 0.35 0.64
105 262 98 0.84
9 21 11 0.64
9%) 34 (83%) 0.69
8%) 9 (22%) 0.65
3%) 4 (10%) 0.66
%) 2/35 (6%) 0.87
clitaxel-eluting stent (PES) patients: n  41; 45 grafts, 57 lesions, 62
t in the BMS group received lepirudin, and 2 patients in the PES group
obtuse marginal; PCI  percutaneous coronary intervention; PDA 
ein graft; TIMI  Thrombolysis In Myocardial Infarction.BM
 39,
55, S
.42
28 (6
12 (2
3 (7
37
16 (3
16 (3
10 (2
1 (2
.13
48 (8
7 (1
1 (2
11 (2
43 (7
4 (7
51 (9
31 (5
16 (2
13 (2
29
12–6
21
8–6
.20
7.1
18
.17
57
20
31 (7
7 (1
5 (1
/30 (7
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The SOS Trial March 17, 2009:919–28linically driven angiographic restudy for documented myo-
ardial ischemia. However, when the Academic Research
onsortium (ARC) criteria were published after the initia-
ion of the study, we included plans to perform an additional
nalysis of definite/probable stent thrombosis with the ARC
efinition (7,8). All events were reviewed and adjudicated by
n independent clinical events committee blinded to treat-
ent allocation.
tatistical analysis. Continuous variables were summa-
ized as mean  1 SD and were compared between the 2
tudy groups with the Student t test or the Wilcoxon
Quantitative Coronary Angiography of 112 Stent
Table 2 Quantitative Coronary Angiography
B
Baseline (n
Before stenting
Reference vessel diameter (mm) 3.29
MLD (mm) 1.04
Diameter stenosis (%) 68
Lesion length (mm) 12
After stenting
In-segment
MLD (mm) 2.51
Diameter stenosis (%) 17
Proximal edge
MLD (mm) 2.86
Diameter stenosis (%) 7
In-stent
MLD (mm) 2.66
Diameter stenosis (%) 13
Acute gain (mm) 1.62
Distal edge
MLD (mm) 2.71
Diameter stenosis (%) 12
Follow-up (n
In-segment
MLD (mm) 1.37
Diameter stenosis (%) 53
Proximal edge
MLD (mm) 2.06
Diameter stenosis (%) 29
In-stent
MLD (mm) 1.39
Diameter stenosis (%) 52
Distal edge
MLD (mm) 1.92
Diameter stenosis (%) 35
Binary angiographic restenosis
In-segment 24
In-stent 24
Late loss
In-segment (mm) 1.17
Proximal edge (mm) 0.80
In-stent (mm) 1.29
Distal edge (mm) 0.82
Values are presented as mean  SD.
MLD  minimal lumen diameter; other abbreviations as in Table 1-sample test. Discrete variables were presented as frequen- ties and group percentages and were compared with the
ikelihood-ratio chi-square or the Fisher exact test.
The primary study end point (binary angiographic reste-
osis at 12-month follow-up coronary angiography) was
nalyzed with the Fisher exact test. The incidence of death,
LR, TVR and non-TVR, target vessel failure, device-
riented composite end point, major adverse cardiac events,
nd stent thrombosis during the follow-up period were
alculated with the Kaplan-Meier method, and the differ-
nces between the 2 study groups were assessed with the
og-rank test. Cox proportional hazards methods were used
VG Lesions
2 Stented SVG Lesions
PES p Value
(n  57)
6 3.17 0.75 0.44
3 1.08 0.49 0.70
67 11 0.51
11 5 0.40
8 2.58 0.57 0.23
17 7 0.92
4 2.87 0.64 0.95
11 81 0.03
8 2.71 0.49 0.60
13 7 0.71
2 1.63 0.38 0.96
9 2.76 0.74 0.67
11 9 0.60
(n  43)
9 2.27 0.79 0.0001
25 21 0.0001
3 2.68 0.82 0.03
14 21 0.09
3 2.31 0.80 0.0001
24 21 0.0001
5 2.62 0.91 0.004
14 20 0.03
4 (9%) 0.0001
4 (9%) 0.0001
8 0.36 0.54 0.0001
7 0.24 0.66 0.06
3 0.42 0.57 0.0001
2 0.20 0.56 0.002ed S
of 11
MS
 55)
 0.8
 0.5
 14
 7
 0.4
 7
 0.5
 6
 0.4
 6
 0.6
 0.5
 9
 47)
 0.9
 34
 1.1
 38
 1.0
 34
 1.2
 40
(51%)
(51%)
 0.9
 1.2
 1.0
 1.1o calculate the hazard ratios for the PES versus BMS
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March 17, 2009:919–28 The SOS Trialroups for each of the aforementioned end points. All
nalyses were performed on an intention-to-treat principle
ith JMP 7.0.1 (SAS Institute, Cary, North Carolina) and
tata (Stata Corporation, College Station, Texas). A 2-sided
value 0.05 was considered statistically significant.
ower calculation. The sample size required for demon-
trating a 66% reduction in binary angiographic restenosis
from 50% to 17%) at 12 months with a 2-sided test with an
lpha error of 0.05 and a power of 80% was 31 patients/
roup. We aimed to enroll 40 patients/group to compensate
or patients whose procedures were unsuccessful or were lost
o follow-up.
esults
atient and procedural characteristics. Between 2005 and
007, 80 patients were enrolled at 5 clinical sites and were
Figure 2 In-Stent MLD Cumulative Frequency
Distributions in the 2 Study Groups
Cumulative frequency distribution curves for minimal luminal diameter (MLD) in
the group that received a bare-metal stent (BMS) and in the group that
received a paclitaxel-eluting stent (PES). (A) The cumulative frequency distribu-
tion curves before and immediately after the intervention. (B) The curves
immediately after intervention and at 12-month follow-up angiography.andomized to a BMS (n  39) or a PES (n  41) (Fig. 1). ahe baseline and procedural characteristics of the 2 study
roups were similar (Table 1). Primary stenting was used in
ost lesions (Table 1). A total of 124 stents were implanted,
4 in the BMS and 64 in the PES group. Procedural success
as achieved in 77 patients (96%). One patient (PES group)
equired emergency coronary bypass surgery due to an
ntrapped Filterwire (Boston Scientific) and 2 patients (1 in
he BMS and 1 in the PES group) developed stent throm-
osis within the first 24 h after stent implantation. Two
atients (1 in each study group) had an asymptomatic
K-MB rise after PCI. One patient (BMS group) had a
emoral hematoma that did not require transfusion, and 1
atient (PES group) had a right external iliac artery dissec-
ion that was successfully stented. An EPD was used in 60
f 112 study lesions (54%). Filterwire (Boston Scientific)
as used in 70% of EPD lesions, Spider (ev3, Plymouth,
innesota) in 12%, Proxis (St. Jude, Maple Grove, Min-
esota) in 12%, and Guardwire (Medtronic, Santa Rosa,
alifornia) was used in 7%.
ngiographic analysis. The primary end point, binary
ngiographic restenosis, could be evaluated in 90 lesions. It
ould not be evaluated in 22 lesions (20%), 16 grafts (18%),
nd 14 patients (18%, 6 BMS and 8 PES patients) (Fig. 1).
ngiographic restenosis occurred in 51% of the BMS-
reated lesions versus 9% of the PES-treated lesions (relative
isk: 0.18; 95% confidence interval [CI]: 0.07 to 0.48, p 
.0001) (Table 2, Fig. 2). The pattern of restenosis was
ocal, intrastent, proliferative, and total occlusion in 9, 2, 2,
nd 11 lesions, respectively, in the BMS group and 2, 0, 0,
nd 2 lesions, respectively, in the PES group. Angiographic
estenosis occurred in 20 of 33 BMS patients (61%) versus
of 33 PES patients (12%) (relative risk: 0.20; 95% CI: 0.08
o 0.52, p  0.0001). Angiographic restenosis occurred in
1 of 37 grafts in the BMS group (57%) versus 4 of 35 grafts
n the DES group (11%) (relative risk: 0.20; 95% CI: 0.08
o 0.53, p  0.0001).
ollow-up. Clinical follow-up was available for all study
atients for a median of 1.5 years (Table 3, Fig. 3). Seven
atients died, 2 (5%) in the BMS and 5 (12%) in the PES
roup (p  0.27) (Fig. 3). The cause of death in the BMS
roup was cardiac arrest in 1 patient and unknown in 1
atient. In the PES group death was due to MI in 1 patient
nd was noncardiac in the remaining 4 patients (lung
ancer, small bowel obstruction, multiple strokes and pneu-
onia, and chronic obstructive pulmonary disease). Clopi-
ogrel use was similar in the 2 groups (Table 3). Compared
ith BMS patients, PES patients had lower rates of TLR
nd target vessel failure (Table 3, Fig. 3). There were trends
oward fewer MIs, TVRs, and ARC definite/probable stent
hrombosis in PES patients (Table 3, Fig. 3). Stroke
ccurred in 1 patient (in the PES group) who subsequently
ied. In addition to the 2 acute stent thromboses, angio-
raphically documented stent thrombosis occurred during
ollow-up in 3 patients, all in the BMS group after 11, 12,
nd 22 months, respectively, from stent implantation.
DT
a
S
i
i
t
i
v
b
(
D
c
m
T
r
a
K
t
f
(
o
g
D
D
o
s
W
B
e
g
s
p
5
(
m
0
w
p
t
c
w
i
m
t
(
A
q
t
p
m
t
t
S
a
r
e
C
D
r
926 Brilakis et al. JACC Vol. 53, No. 11, 2009
The SOS Trial March 17, 2009:919–28iscussion
he most important finding of this trial is that PES reduce
ngiographic restenosis rates and target vessel failure in
VG lesions compared with BMS.
Drug-eluting stents have been shown to reduce restenosis
n many lesion types and clinical syndromes. However, there
s a paucity of prospective data on DES in SVG interven-
ions, although BMS is associated with high restenosis rates
n SVG lesions. The results of mostly retrospective obser-
ational series comparing DES with BMS in SVGs have
een conflicting: 6 studies showed better results with DES
9–14) and 9 suggested no difference between BMS and
ES (15–23).
The SOS trial is the first prospective, randomized,
ontrolled trial of PES in SVG lesions and the first
ulticenter DES clinical trial of any kind in SVG lesions.
wo prospective, randomized, single-center studies have
eported comparisons of DES and BMS in SVG lesions. In
post hoc subgroup analysis of the BASKET (Basel Stent
osten Effektivitats Trial) study, the subgroup of 47 pa-
ients who underwent SVG PCI derived greater benefit
rom DES implantation during a follow-up of 18 months
24). In the BASKET study, major adverse cardiac events
ccurred in 62% in the BMS group versus 21% in the DES
roup (p  0.007), mainly due to a lower TVR rate in the
ES group (46% vs. 18%, p  0.04).
In the only published, prospective, randomized trial of
ES versus BMS in SVG lesions, the RRISC (Reduction
f Restenosis In Saphenous vein grafts with Cypher
irolimus-eluting stent) trial, an SES (Cypher, Cordis,
linical Events and Clopidogrel Use During Follow-Up
Table 3 Clinical Events and Clopidogrel Use During Follow-Up
BMS
(n  39)
Clinical events, n (%)
Death 2 (5%
MI 12 (31%
TLR 11 (28%
TVR 12 (31%
Any revascularization 16 (41%
Death or MI 13 (33%
Target vessel failure 18 (46%
Device-oriented composite end point 17 (44%
Overall major adverse cardiac events
(patient-oriented composite end point)
19 (49%
Definite or probable stent thrombosis by ARC criteria 5 (13%
Clopidogrel use, n/total (%)
6 months 33/37 (89%
12 months 23/31 (74%
18 months 14/22 (64%
24 months 6/12 (50%
evice-oriented composite end point  composite of cardiac death, target vessel MI, and target l
ARC  Academic Research Consortium; CI  confidence interval; HR  hazard ratio; Overal
evascularization; TLR  target lesion revascularization; TVR  target vessel revascularization; otarren, New Jersey) was compared with a similar BMS, the rxVelocity stent (Cordis) (2,3). Overall, 75 patients were
nrolled, and 96 lesions were treated in 80 SVGs. Angio-
raphic follow-up after only 6 months revealed less in-
egment restenosis in the SES arm (13.6% vs. 32.6%,
 0.031). Repeat TVR within 6 months was performed in
.3% of patients in the SES versus 27% in the BMS group
p  0.012) (2). However, after a median of 32 months,
ortality was higher in the SES group (29% vs. 0%, p 
.001), and the early benefits of SES were lost: no difference
as seen in the incidence of MI (18% SES vs. 5% BMS,
 0.15) or TVR (34% SES vs. 38% BMS, p 0.74) (3). Of
he 11 deaths in the SES group, 1 was due to angiographically
onfirmed late stent thrombosis and 3 were sudden.
As in the RRISC trial, a significant reduction in late loss
as observed in the DES arm of SOS. The in-stent late loss
n the DES group was similar in the 2 studies (0.38  0.51
m in the RRISC trial, and 0.42  0.57 mm in the SOS
rial) but was less in the BMS group in the RRISC study
0.79  0.66 mm) than in the SOS trial (1.29  1.03 mm).
ccordingly, angiographic restenosis occurred more fre-
uently in the BMS arm of the SOS trial (51% vs. 33% in
he RRISC trial). This was likely in part due to the
erformance of follow-up coronary angiography at 12
onths in the SOS trial versus at 6 months in the RRISC
rial. The higher prevalence of diabetes (44% in the SOS
rial vs. 15% in the RRISC trial) and smoking (26% in the
OS trial vs. 8% in the RRISC trial) might have also played
role. In contrast to the RRISC study, where most
estenoses were nonocclusive, nearly one-half of the rest-
notic lesions in the SOS trial were occlusive, in which
DES
(n  41) HR (95% CI) p Value
5 (12%) 1.56 (0.72–4.11) 0.27
6 (15%) 0.67 (0.40, 1.08) 0.10
2 (5%) 0.38 (0.15–0.74) 0.003
6 (15%) 0.66 (0.39, 1.05) 0.08
8 (20%) 0.59 (0.37–0.91) 0.02
10 (24%) 0.82 (0.54–1.24) 0.34
9 (22%) 0.65 (0.42–0.96) 0.03
6 (15%) 0.54 (0.32–0.83) 0.005
15 (37%) 0.80 (0.57–1.12) 0.20
1 (2%) 0.42 (0.10–1.05) 0.07
39/40 (98%) 0.14
28/34 (82%) 0.42
13/19 (68%) 0.75
7/12 (58%) 0.68
vascularization.
adverse cardiac events  composite of any death, any myocardial infarction, or any coronary
reviations as in Table 1.)
)
)
)
)
)
)
)
)
)
)
)
)
)
esion re
l major
her abbepeat PCI is often not attempted, explaining in part why
t
i
a
R
B
s
t
i
S
h
n
g
t
s
a
r
(
m
S
a
S
n
f
t
p
t
t
p
s
b
e
o
n
w
a
c
t
927JACC Vol. 53, No. 11, 2009 Brilakis et al.
March 17, 2009:919–28 The SOS Trialhe difference in TVR did not reach statistical significance
n the SOS trial.
The PES group in the SOS trial had less TLR without
ttenuation of benefit during follow-up, as was seen in the
RISC trial. Both the Express2 BMS used in SOS and the
xVelocity BMS (Cordis) used in the RRISC trial are thick
trut stents (strut thickness 132 and 140 m, respectively);
herefore, BMS design is unlikely to explain the higher
n-stent restenosis rates in the BMS arm of the SOS trial.
Mortality was similar in the BMS and DES arms of the
OS trial. Although total mortality rates were numerically
igher in the PES arm (5 vs. 2), most deaths were
oncardiac; only 2 cardiac deaths occurred in the BMS
roup, and 1 cardiac death occurred in the PES group. A
rend toward a lower incidence of MI in the PES group
hould further allay fears of a late increase in cardiac deaths
s a result of placement of a PES in an SVG. Larger
andomized trials are needed to evaluate the impact of DES
and differences between PES and SES or other DES) on
Figure 3 Kaplan-Meier Curves of the Study’s Clinical End Point
No difference in overall mortality was found between the study groups (A). A trend
(PES) group (B). The incidence of target lesion revascularization (C) and of target
target vessel revascularization, was significantly lower in the PES group than the bortality, MI, and stent thrombosis. gtudy limitations. Although the SOS trial is the largest
nd first multicenter trial comparing DES and BMS in
VGs, it is nonetheless limited by the relatively small
umber of patients enrolled and the losses to angiographic
ollow-up, although the loss to angiographic follow-up in
he SOS trial (18%) was similar to that achieved in the
ivotal trials of all 4 currently Food and Drug Administra-
ion–approved DES. The SOS trial was powered for de-
ecting angiographic restenosis and was therefore under-
owered to detect differences in clinical outcomes, although
ignificant differences in clinical outcomes were observed
etween the study groups. All patients enrolled were male;
ven though sex differences have not surfaced in any of the
ther DES versus BMS trials, the results of this study might
ot apply to women. Although all repeat revascularizations
ere driven by clinical symptoms, the protocol-required
ngiographic follow-up might have increased rates of repeat
oronary revascularizations in both study groups and par-
icularly in the BMS arm, because late loss was so much
wer incidence of myocardial infarctions was seen in the paclitaxel-eluting stent
l failure (D), composite end point of cardiac death, myocardial infarction, and
tal stent (BMS) group.s
for lo
vesse
are-mereater in that arm. The study was single-blinded, although
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he clinical events were performed blinded to stent alloca-
ion. The median follow-up of SOS patients was 1.5 years;
t is unknown whether the outcomes would change with
onger-term follow-up. The outcomes seen with PES might
ot apply to other DES. Although the post-PCI MI rates
ere low in our study and the use of EPDs was similar in
oth study groups, more frequent use might have led to
etter outcomes in both groups.
onclusions
he use of PES in SVG lesions is associated with lower
ates of angiographic restenosis and target vessel failure
han BMS. Large, prospective, multicenter, randomized-
ontrolled clinical trials that use a clinical rather than
ngiographic end point are needed to confirm the beneficial
ole of DES in SVG lesions (25).
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